Revolution Medicines, Inc. (RVMD) est une société cotée en bourse dans le Santé secteur, opérant dans le Biotechnologie secteur d'activité. Le siège social de l'entreprise est situé à Redwood City, CA, United States. Le PDG actuel est Mark A. Goldsmith.
RVMD a date d'introduction en bourse 2020-02-13, 616 employés à temps plein, cotée sur le NASDAQ Global Select, une capitalisation boursière de $29.13B.
Revolution Medicines, Inc. is a clinical-stage precision oncology company focused on developing novel therapies targeting RAS-addicted cancers. The company's pipeline includes several investigational programs, such as RMC-4630, an SHP2 inhibitor currently in Phase 1/2 trials for solid tumors including gynecologic and colorectal cancers, as well as RMC-5845, RMC-5552, RMC-6291, and RMC-6236, which target various components of RAS signaling pathways. Revolution Medicines has established a collaboration with Sanofi for the research and development of SHP2 inhibitors. Founded in 2014 and based in Redwood City, California, the company is advancing precision medicine approaches to address cancers driven by RAS mutations.
